

Cai-Cun Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/645814/publications.pdf>

Version: 2024-02-01

63
papers

7,710
citations

218381

26
h-index

123241

61
g-index

65
all docs

65
docs citations

65
times ranked

8133
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 735-742.	5.1	3,758
2	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	5.1	1,369
3	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer (Camel): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 305-314.	5.2	277
4	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	0.5	260
5	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	196
6	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 681-690.	5.2	166
7	Long non-coding RNA <i>UCA1</i> induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in <i>EGFR</i> -mutant non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 23582-23593.	0.8	144
8	Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1383-1392.	0.5	140
9	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 110-120.	0.5	108
10	T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. <i>Lung Cancer</i> , 2014, 84, 295-300.	0.9	81
11	Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. <i>Oncology Reports</i> , 2015, 33, 833-839.	1.2	80
12	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 1296-1304.	3.2	79
13	Correlation of long non-coding RNA <i>H19</i> expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 2558-2567.	0.8	70
14	Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients. <i>Translational Oncology</i> , 2014, 7, 341-348.	1.7	68
15	Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of <i>EGFR</i> , <i>ALK</i> , <i>ROS1</i> , <i>KRAS</i> or <i>BRAF</i> . <i>Cancer Medicine</i> , 2019, 8, 2858-2866.	1.3	59
16	Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3486-3494.	3.2	56
17	Hypoxia-induced cell stemness leads to drug resistance and poor prognosis in lung adenocarcinoma. <i>Lung Cancer</i> , 2015, 87, 98-106.	0.9	55
18	Long non-coding RNA <i>UCA1</i> promotes lung cancer cell proliferation and migration via microRNA-193a/HMGB1 axis. <i>Biochemical and Biophysical Research Communications</i> , 2018, 496, 738-745.	1.0	55

#	ARTICLE	IF	CITATIONS
19	First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. <i>Journal of Cancer</i> , 2019, 10, 522-529.	1.2	43
20	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9020-9020.	0.8	39
21	Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 61, 103-114.	1.2	37
22	miR-512-5p induces apoptosis and inhibits glycolysis by targeting p21 in non-small cell lung cancer cells. <i>International Journal of Oncology</i> , 2016, 48, 577-586.	1.4	35
23	Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 100801-100818.	0.8	35
24	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) <i>Tj ETQq0 0.0 rgBT /Overlock 10</i>	0.7	34
25	Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small cell lung cancer. <i>Histopathology</i> , 2015, 66, 949-954.	1.6	32
26	Rapid Detection of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Using Real-Time Polymerase Chain Reaction with TaqMan-MGB Probes. <i>Cancer Journal (Sudbury, Mass)</i> , 2006, 12, 33-39.	1.0	28
27	Prophylactic Cranial Irradiation May Impose a Detrimental Effect on Overall Survival of Patients with Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e103431.	1.1	27
28	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 126-131.	0.9	26
29	Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2013, 13, 329-336.	0.8	24
30	Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer. <i>Thoracic Cancer</i> , 2015, 6, 407-412.	0.8	24
31	HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition. <i>Lung Cancer</i> , 2020, 147, 99-105.	0.9	21
32	Transcutaneous electrical acupoint stimulation (TEAS) relieved cancer-related fatigue in non-small cell lung cancer (NSCLC) patients after chemotherapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 1959-1966.	0.6	20
33	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). <i>Patient</i> , 2018, 11, 131-141.	1.1	20
34	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1857-1870.	0.5	19
35	Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 840313.	2.2	19
36	The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1149-1158.	1.3	17

#	ARTICLE	IF	CITATIONS
37	Serum Levels of the Cancer-Testis Antigen POTEE and Its Clinical Significance in Non-Small-Cell Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0122792.	1.1	16
38	The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 671874.	1.3	14
39	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0142500.	1.1	14
40	High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations. <i>Translational Lung Cancer Research</i> , 2021, 10, 1512-1524.	1.3	13
41	Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, e103-e112.	1.1	11
42	Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage III small cell lung cancer. , 2021, 9, e002554.		11
43	Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 441-441.	0.7	11
44	Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. <i>Lung Cancer</i> , 2022, 167, 25-33.	0.9	9
45	Comparison among different presentations of venous thromboembolism because of lung cancer. <i>Clinical Respiratory Journal</i> , 2019, 13, 574-582.	0.6	8
46	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7
47	Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100312.	0.6	7
48	The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. <i>Translational Lung Cancer Research</i> , 2021, 10, 3929-3942.	1.3	6
49	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. <i>Targeted Oncology</i> , 2022, 17, 1-13.	1.7	6
50	Expression of Collagen IV, Fibronectin, Laminin in Non-small Cell Lung Cancer and Its Correlation with Chemosensitivities and Apoptosis. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 58-62.	0.1	4
51	Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint. <i>Journal of Thoracic Oncology</i> , 2020, 15, 485-488.	0.5	4
52	The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review. <i>Journal of Thoracic Disease</i> , 2021, 13, 5093-5103.	0.6	4
53	Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1622-1626.	0.5	4
54	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Value of heart rate recovery in female patients with pulmonary arterial hypertension due to systemic lupus erythematosus. <i>Clinical Respiratory Journal</i> , 2019, 13, 545-554.	0.6	3
56	Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study,) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Jf 50 702 T</i> 338-338.	0.7	3
57	Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20575-e20575.	0.8	3
58	Editorial: Lung cancer: continuous progress in diagnosis and treatment. <i>Current Opinion in Oncology</i> , 2022, 34, 29-31.	1.1	3
59	Influence of comorbidity on the choice of treatment and survival of elderly patients with advanced non-small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2008, 7, 259-262.	0.1	1
60	Combination chemotherapy with irinotecan and cisplatin as second-line treatment for small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2008, 7, 451-454.	0.1	1
61	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9077-9077.	0.8	1
62	Gefitinib in the treatment of 41 cases with refractory non-small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2009, 8, 314-316.	0.1	0
63	CLO22-089: BC200 Mediates Immune Escape in NSCLC by Affecting Tumor-Immune Microenvironment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, CLO22-089.	2.3	0